Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13685883 | 0.81 | TMEM97 (0.53) | TMEM97RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL220610 | 0.80 | TMEM97 (0.57) | TMEM97RAB9AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL13105644 | 0.79 | TMEM97 (0.59) | TMEM97RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12861015 | 0.79 | MAOB (0.58) | TMEM97ALDH1A1 | |
| SCHEMBL3122259 | 0.76 | TMEM97 (0.48) | TMEM97RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13016805 | 0.76 | TMEM97 (0.48) | TMEM97RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8026418 | 0.76 | ALDH1A1 (0.64) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3112716 | 0.75 | TMEM97 (0.50) | TMEM97RAB9AALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL17369723 | 0.75 | TMEM97 (0.47) | TMEM97RAB9A | |
| SCHEMBL6533444 | 0.74 | TMEM97 (0.55) | TMEM97RAB9AALDH1A1ATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2620433-B1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-13 | — | — | EP | disclosed |
| EP-2481725-B1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-8815920-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8669246-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-09-05 | — | — | US | disclosed |
| EP-2620433-A1 | SUBSTITUTED AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-8222277-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-07-17 | — | — | US | disclosed |
| US-7754772-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX, S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-1539729-A4 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1539729-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NITROMED, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2004004648-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NOS2, NOS1, NOS3 | TMEM97 2102/4885RAB9A 2571/4885ALDH1A1 383/4885 |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | TMEM97 2057/4885RAB9A 2590/4885ALDH1A1 385/4885 |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | TMEM97 986/4885RAB9A 1443/4885ALDH1A1 3512/4885 |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | TMEM97 2057/4885RAB9A 2590/4885ALDH1A1 385/4885 |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | TMEM97 924/4885RAB9A 1308/4885ALDH1A1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.